Lilly describes pro forma impact of acquisition

Lilly has filed a report detailing the pro forma impact of the acquisition of ImClone.

The company’s submission of Form 8-K/A details unaudited pro forma condensed and combined financial statements of the two companies, for the year up to December 31st 2007.

Lilly added it also includes information of the nine months up to September 30th last year.

Earlier this month, the company announced a date it would declare its financial results for the fourth quarter and the full 12 months of 2008.

Set to take place on January 29th, Lilly added it will also conduct a conference call, in order to shed further light on the organisation’s current financial performance.

A webcast will be available on the company’s website, with a replay available for investors through February 27th.

Founded in 1876, Lilly is based in Indianapolis, US and currently employs 40,217 people around the world, of which 7,946 are engaged in research and development.

The company has clinical research capabilities in more than 50 countries, along with research and development facilities in eight.

Additionally, it has manufacturing plants in 13 principalities, along with the marketing of its products in 143.